GlassScriptPhysician profile
Adelene Soto
NPI 1003049990
$757.62
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
See the full distribution for Pediatrics (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $494 · 2022: $172 · 2023: $39.68 · 2024: $51.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $91.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $91.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $131.98 | 2021-2022 | |
| Tris Pharma INC | $124.54 | 2021-2024 | Dyanavel Xr |
| Ucb, INC. | $95.78 | 2021 | |
| Corium, LLC | $82.01 | 2021-2024 | Azstarys |
| Aquestive Therapeutics, INC. | $68.51 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.27 | 2021 | |
| Neurelis, INC. | $48.75 | 2021 | |
| Sunovion Pharmaceuticals INC. | $37.48 | 2021 | |
| Eisai INC. | $23.11 | 2023 | |
| Sk Life Science, INC. | $18.29 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $16.57 | 2023 | Rexulti |
| Immedica Pharma US, INC. | $14.65 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.95 | 2021 | |
| Ironshore Pharmaceuticals INC. | $13.84 | 2021 | |
| Biomarin Pharmaceutical INC. | $12.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adelene Soto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.